CME/CE Web Article
Release Date: January 2007
Expiration Date: January 31, 2008
Program Overview
The term “diabetic microvascular complications” (DMC) refers to 3 specific chronic complications of diabetes: retinopathy, nephropathy, and peripheral neuropathy. These complications are common and create heavy personal, social, and economic burdens. The purpose of this activity is to increase understanding of the shared mechanisms underlying DMC and to increase awareness of emerging pharmacotherapies for their treatment.
Intended Audience
This activity was developed for diabetologists, endocrinologists, primary care physicians, related diabetes specialists, and nurses involved in diabetes care.
Method of Participation and Obtaining Continuing Education Credit
The participant should: 1) view the content presented; 2) take the post-test; 3) complete and submit the continuing education registration and evaluation forms for credit. This activity should take approximately 90 minutes to complete. The expiration date for this activity is January 31, 2008. No credit will be granted after this date.
Continuing education credit is offered upon successful completion of the post-test. Certificates will be issued to participants approximately 3 to 4 weeks after receipt of both the registration and evaluation forms and successful completion of the post-test with a passing score of 80% or higher.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
-
Identify metabolic and cell signaling pathways that are theorized to contribute to microvascular damage when overactivated by hyperglycemia
-
Describe mechanisms by which overactivation of some metabolic and cell signaling pathways leads to microvascular damage
-
Explain how microvascular damage contributes to tissue damage associated with diabetic microvascular complications (DMC)
-
State the clinical presentations of DMC
-
Explain how interrupting specific metabolic and cell signaling pathways could affect the development and progression of DMC
-
Discuss clinical benefits of interrupting metabolic and cell signaling pathways that contribute to the development and progression of DMC
Accreditation Statement for Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Center for Accredited Healthcare Education (CAHE), the Institute for Medical and Nursing Education (IMNE), and International Medical Press (IMP). CAHE is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement for Physicians
The Center for Accredited Healthcare Education designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Accreditation Statement for Nurses
The Institute for Medical and Nursing Education (IMNE) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Credit Designation Statement for Nurses
The Institute for Medical and Nursing Education designates this educational activity for 1.5 contact hours (0.15 CEU).
Disclosures
In compliance with Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center 's Commission on Accreditation (ANCC), it is the policy of CAHE and IMNE to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, CME/CE provider staff, faculty, and planners) are expected to disclose any significant financial relationships with commercial interests over the past 12 months. CAHE and IMNE also require that faculty identify and reference off-label product or investigational use of pharmaceutical and medical device products.
All conflicts of interest have been mitigated and resolved through the use of an external peer review process.
AUTHOR
Martin Abrahamson, MD
Speaker’s Bureau: AstraZeneca, Aventis, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Merck, Novo Nordisk, Novartis, Pfizer, Takeda
Research Activities: Pfizer
Dr Abrahamson has disclosed that he anticipates discussing unlabeled uses of tricyclic agents and anticonvulsants for the treatment of painful diabetic neuropathy.
Dr Abrahamson has disclosed that he anticipates discussing investigational products in this educational activity, including aminoguanidine, ruboxistaurin, antioxidants, and aldose reductase inhibitors.
REVIEWER
Scott V Joy, MD, CDE, FACP
Formal Advisor: Eli Lilly and Company, Amylin Pharmaceuticals Inc
CME/CE PROVIDER AND EDUCATIONAL PARTNER STAFF
All staff of CAHE, IMNE, and IMP in a position to influence content have filed statements of disclosure with the CME and CE provider. Any conflicts of interest were identified and resolved prior to their involvement in planning this activity. Disclosures are available for review by contacting Steve Weinman at 1 609 936 7015 or e-mail at steve.weinman@cahe.com.
CAHE, IMNE, and IMP staffs have disclosed no conflicts of interest.
Disclaimer
This activity is designed for healthcare professionals for educational purposes. Information and opinions offered by the faculty/presenters represent their own viewpoints. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information.
While the Center for Accredited Healthcare Education and Institute for Medical and Nursing Education make every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Commercial Support Acknowledgement
This activity is supported by an educational grant from Eli Lilly and Company.
Site Requirements
WINDOWS
- 266 MHz CPU (600MHz recommended)
- Windows 98 or higher
- 64 MB RAM
- 800 x 600 screen resolution, thousands of colors (1024 X 768, millions of colors [32 bit] recommended)
- Browser: Internet Explorer 5.0 or higher; Netscape 4.7, 6.2, or higher
- Plug-ins: Flash, Shockwave, QuickTime, and Chime
- NOTE: Use of Netscape 6.0 is not recommended due to a known incompatibility with the Shockwave plug-in. (You may obtain the current version of these browsers for Windows by clicking on Internet Explorer download or Netscape download , then follow the online instructions.)
MACINTOSH
- 266 MHz CPU
- OS 8.6 or higher
- 64 MB RAM
- 800 x 600 screen resolution, thousands of colors
- Browser:
OS 8-9 : Netscape 4.7, 6.2, or higher (Web only: Internet Explorer 5 or higher)
OS X : Internet Explorer 5.2 or higher; Netscape 6.2 or higher
- Plug-ins: Flash, Shockwave, QuickTime, and Chime
- NOTE: Use of Netscape 6.0 is not recommended due to a known incompatibility with the Shockwave plug-in. (You may obtain the current version of these browsers for Macintosh by clicking on Internet Explorer download or Netscape download , then follow the online instructions.)
ALL COMPUTERS
